Online inquiry

IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7934MR)

This product GTTS-WQ7934MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7934MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13423MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ15899MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ3201MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ1008MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ8395MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ10209MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ9904MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ15057MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SRF-231
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW